Biopharma Clinical Development
WES & WTS provide assurances to your clinical development programs with data-driven decisions.
Unmatched breadth and depth of profiling coverage
TISSUE PROFILING
Caris analyzes 23,000 genes through DNA, RNA and proteins with Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and Immunohistochemistry (IHC).
BLOOD-BASED PROFILING
Overcome the challenges of insufficient material, poor sensitivity and false positives by analyzing DNA, RNA, and identifying somatic CHIP mutations.
MI Trials
Accelerate enrollment by identifying biomarker+ patients from our extensive network of clinical sites, supported by dedicated clinical trial nurse navigators.
MI Trials offers patients and physicians access to the latest drugs being developed to improve clinical outcomes. According to National Cancer Institute statistics, awareness of available trials is low and overall participation in oncology trials is less than five percent. Caris helps increase awareness and participation of clinical trials through Caris Trial Solutions.
Right-in-Time Research
Right-In-Time (RIT) research is a rapid start-up/enrollment process where research sites screen for patients prior to activation. The purpose of the program is to reduce the burden on research facilities, which allows them access to a larger number of potential trials when they have an eligible patient. This allows physicians at Caris RIT sites to include clinical trials, not yet opened, in their treatment options for current and future patients.
Real World Data, Caris Context
Access a dedicated cross-functional team to address questions and enhance programs by leveraging Caris’ clinico-genomic database of more than 482K matched profiles.
DEEP MOLECULAR PROFILING
593,000+ profiles
MATCHED CLINICAL PROFILES
482,000+ profiles
ARTIFICIAL INTELLIGENCE
9 MILLION+ FFPE SLIDES
IHC + H&E DIGITIZED
23 FULL-TIME PATHOLOGISTS
AI-GUIDED PATHOLOGY
DEEP MOLECULAR PROFILING
430,000+ profiles
MATCHED CLINICAL PROFILES
275,000+ profiles
ARTIFICIAL INTELLIGENCE
Uncover the complete molecular and clinical context to deliver
on the promise of precision medicine.
Caris has amassed a longitudinal multiomic data library that spans over 482k+ patients across 55+ indications. Biopsies come to Caris for sequencing across the standard of care. Our partners can interrogate the data to understand the tumor biology within the context of clinical care. Caris RWD is an unmatched resource for discovery and clinical development programs.
Available data include, but is not limited to:
- WES & WTS
- Imaging (IHC, H&E)
- Treatments (e.g. medication, including surgery, radiation)
- Outcomes (e.g. progression events, responses, death)
- Key demographics
Longitudinal multiomic data has been employed by biopharma to:
- Assess the effects of treatments on gene expression and the mutational landscape
- Understand outcomes to specific therapies for biomarker cohorts of interest
- Investigate dynamics of the tumor microenvironment: immune cell infiltration, target expression, hot/cold designation
- Identify the ideal patient population for clinical assets
ACTIONABLE INSIGHTS FOR BIOPHARMA CAN BE UNLOCKED BY FIVE CORE DATA PILLARS
Contact Us
"*" indicates required fields